S. Qureshi

发表

Detection of insulin receptor tyrosine kinase activity using time-resolved fluorescence energy transfer technology.

D. Moller, D. E. Biazzo-Ashnault, Y. W. Park, 2001, Analytical biochemistry.

A novel series of indazole-/indole-based glucagon receptor antagonists.

S. Qureshi, Bei B. Zhang, G. Salituro, 2015, Bioorganic & medicinal chemistry letters.

A Genome-Wide siRNA Screen to Identify Modulators of Insulin Sensitivity and Gluconeogenesis

Xiaohua Douglas Zhang, M. Ferrer, Kenny K. Wong, 2012, PloS one.

Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists.

V. Ding, S. Qureshi, K. Chapman, 2005, Bioorganic & medicinal chemistry letters.

RNAi-mediated germline knockdown of FABP4 increases body weight but does not improve the deranged nutrient metabolism of diet-induced obese mice

T. Vogt, J. Berger, B. Zhang, 2010, International Journal of Obesity.

A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects.

D. Moller, V. Ding, S. Qureshi, 2004, Diabetes.

Discovery of potent, orally active benzimidazole glucagon receptor antagonists.

V. Ding, S. Qureshi, D. Szalkowski, 2008, Bioorganic & medicinal chemistry letters.

Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor.

V. Ding, S. Qureshi, D. Szalkowski, 2005, Bioorganic & medicinal chemistry letters.

Cloning and expression of canine glucagon receptor and its use to evaluate glucagon receptor antagonists in vitro and in vivo.

J. Berger, S. Qureshi, Bei B. Zhang, 2007, European journal of pharmacology.

Anti-Diabetic Efficacy and Impact on Amino Acid Metabolism of GRA1, a Novel Small-Molecule Glucagon Receptor Antagonist

Margaret S. Wu, S. Qureshi, J. Mu, 2012, PloS one.

Detection of Glucagon-Dependent GTPγS Binding in High-Throughput Format

S. Qureshi, Bei B. Zhang, Q. Dallas-yang, 2002 .

Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists.

J. Fenyk-Melody, S. Qureshi, D. Szalkowski, 2004, European journal of pharmacology.

Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes.

S. Qureshi, S. Xu, Bei B. Zhang, 2012, Journal of medicinal chemistry.

Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice

S. Qureshi, G. Jiang, J. Mu, 2011, Diabetologia.

Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core.

V. Ding, S. Qureshi, K. Chapman, 2011, Bioorganic & medicinal chemistry letters.

Discovery of N-aryl-2-acylindole human glucagon receptor antagonists.

V. Ding, S. Qureshi, D. Szalkowski, 2011, Bioorganic & medicinal chemistry letters.

Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists.

V. Ding, S. Qureshi, D. Szalkowski, 2011, Bioorganic & medicinal chemistry letters.

Regulation of insulin signal transduction pathway by a small-molecule insulin receptor activator.

D. Moller, D. E. Biazzo-Ashnault, V. Ding, 2002, The Biochemical journal.

Functional STAT 1 and 3 signaling by the leptin receptor (OB-R); reduced expression of the rat fatty leptin receptor in transfected cells.

M. Phillips, T. M. Fong, M. Tota, 1996, Endocrinology.

Activation of Insulin Signal Transduction Pathway and Anti-diabetic Activity of Small Molecule Insulin Receptor Activators*

D. Moller, D. E. Biazzo-Ashnault, V. Ding, 2000, The Journal of Biological Chemistry.